LAMY engages in developing a business tapping the eLearning market and the gaming market by teaching financial knowledge and resource management to children. The company is headquartered in St. Petersburg, Florida. The company went IPO on 2024-04-30. The firm is engaged in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with genetic functionality, capable of selectively targeting specific cells to address diseases with unmet medical needs. The engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. Its proprietary manufacturing process utilizes plant-based materials to create exosomes used in various commercial applications, including dermatology and dentistry.
最新の財務諸表(Form-10K)によると、Lee & Man Paper Manufacturing Limitedの総資産は$57,688で、純利益は$1,941です。
LMMYの主要な財務比率は何ですか?
Lee & Man Paper Manufacturing Limitedの流動比率は2.11、純利益率は7.28、1株当たり売上高は$6.2です。
LAMYの収益はセグメントまたは地域別にどのように分けられていますか?
Lee & Man Paper Manufacturing Limited の最大収益セグメントは Packaging Paper で、最新の利益発表における収益は 20,102,823,000 です。地域別に見ると、China が Lee & Man Paper Manufacturing Limited の主要市場であり、収益は 23,135,924,690 です。
LAMYは収益を上げていますか?
はい、最新の財務諸表によると、Lee & Man Paper Manufacturing Limitedの純利益は$1,941です。
LAMYに負債はありますか?
はい、Lee & Man Paper Manufacturing Limitedの負債は27,252です。
LAMYの発行済株式数は何株ですか?
Lee & Man Paper Manufacturing Limitedの総発行済株式数は4,295株です。